SomaLogic tops Wall Street sales estimates despite growing loss

BOULDER — SomaLogic Inc. (Nasdaq: SLGC) posted revenues in the first quarter of 2023 that surpassed Wall Street analysts’ expectations, sending the company’s stock upwards on Friday despite a balloon net loss compared to the same period last year. 

The Boulder life-sciences firm develops platforms to read thousands of proteins in a patient’s blood or urine sample that may signal illnesses or future health conditions and suggest potential treatments via machine learning.

Revenue for the first quarter of this year were $20.4 million, down from $23 million in the same period last year. 

SPONSORED CONTENT

Exploring & expressing grief

Support groups and events, as well as creative therapies and professional counseling, are all ways in which Pathways supports individuals dealing with grief and loss.

Still, the sales figure topped Zacks Consensus Estimate by more than 10%.

Net loss was $34.2 million in the most recent quarter, or a loss of $0.18 per share, as compared to a loss of $4.0 million, or $0.02 per share, in the corresponding period of 2022.

“My focus at SomaLogic is fiscal discipline and commercial execution,” SomaLogic’s interim CEO Adam Taich said in a prepared statement. “We are expanding the ways in which customers can engage with our platform and building our customer base on a global scale. I look forward to working closely with our new board leadership to make the necessary strategic decisions to build a sustainable and profitable business in this dynamic and growing life science industry.”

Looking ahead, SomaLogic expects sales to total $80 million to $84 million for the full 2023 fiscal year. 

The company’s stock price finished trading Friday at $3.06, up 2%.

This article was first published by BizWest, an independent news organization, and is published under a license agreement. © 2023 BizWest Media LLC.